Study B7981080 for Non-Segmental Vitiligo

Study ID: B7981080 for Vitiligo

This study is to test the safety and effectiveness of a once daily oral treatment for non segmental vitiligo.

Currently there are no oral medications approved for treating non segmental vitiligo.

The study drug has already been approved for use in treating another autoimmune condition, but its effectiveness in treating vitiligo still requires research.

This is a placebo controlled trial, which means there is a possibility you will receive the placebo (which has no medicine).
There is a greater chance to receive the active drug than the placebo.

Study medicine and any trial-related
procedures are generally covered at no cost.

Recruitment

Your participation in our clinical trial helps develop treatments that can help millions of people.

If you have non segmental vitiligo, and want to help us research innovative treatments by trying them with us, read on to the inclusion criteria.   

Inclusion Criteria

You are eligible* to participate in the study if:

You are 18 or older.

You have been diagnosed with non segmental vitiligo for at least 3 months.

Your vitiligo is either active or stable.

You have vitiligo on both your face and body, covering between 4% and 60% of your body.

* Additional criteria for eligibility apply

If you participate in the B7981080 Study, You will be asked to:**

Provide signed informed consent

Comply with all scheduled clinic
visits and study-related
procedures

Not take any study-prohibited
medications during the trial
period

** Additional responsibilities apply

Your participation in the study is entirely voluntary, and your information
will be confidential.

If you change your mind, you can withdraw from the study at any
time, for any reason, and without any consequence

What to expect during the study

Beyond the initial screening period, the study lasts up to 26 months
consisting of up to 17 clinic visits to update on your health status, including:***